Septerna (NASDAQ:SEPN) Sets New 52-Week Low – Here’s What Happened

Septerna, Inc. (NASDAQ:SEPN)’s stock price reached a new 52-week low during mid-day trading on Saturday . The company traded as low as $17.71 and last traded at $17.99, with a volume of 207078 shares trading hands. The stock had previously closed at $20.85.

Wall Street Analysts Forecast Growth

SEPN has been the topic of a number of research analyst reports. JPMorgan Chase & Co. initiated coverage on Septerna in a research note on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 target price on the stock. Cantor Fitzgerald initiated coverage on Septerna in a research note on Tuesday, November 19th. They issued an “overweight” rating and a $50.00 target price on the stock. Wells Fargo & Company initiated coverage on Septerna in a research note on Tuesday, November 19th. They issued an “overweight” rating and a $43.00 target price on the stock. Finally, TD Cowen assumed coverage on Septerna in a research note on Tuesday, November 19th. They issued a “buy” rating on the stock.

Septerna Stock Down 13.7 %

The firm has a 50 day simple moving average of $23.63.

Insider Buying and Selling at Septerna

In other news, major shareholder Rock Ventures V. L.P. Third bought 370,500 shares of Septerna stock in a transaction dated Monday, October 28th. The shares were purchased at an average cost of $18.00 per share, with a total value of $6,669,000.00. Following the completion of the acquisition, the insider now owns 6,215,591 shares of the company’s stock, valued at $111,880,638. This trade represents a 6.34 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.